Current Liabilities
Accrued Manufacturing Costs
Pfizer Accrued Manufacturing Costs decreased by 24.8% to $2.72B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.1%, from $2.61B to $2.72B. Over 5 years (FY 2020 to FY 2025), Accrued Manufacturing Costs shows an upward trend with a 3.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2014
Last reportedQ1 2026May 5, 2026
Metric ID:
accrued_manufacturing_costsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.02B | $2.57B | $3.33B | $2.25B | $2.00B | $2.85B | $3.41B | $2.28B | $1.97B | $2.37B | $2.78B | $2.19B | $2.57B | $3.38B | $3.84B | $2.61B | $2.45B | $3.04B | $3.61B | $2.72B |
| QoQ Change | — | +27.6% | +29.6% | -32.5% | -11.2% | +42.8% | +19.5% | -33.2% | -13.4% | +20.3% | +17.0% | -21.0% | +17.1% | +31.8% | +13.4% | -32.1% | -6.1% | +24.1% | +18.9% | -24.8% |
| YoY Change | — | — | — | — | -0.9% | +10.9% | +2.3% | +1.2% | -1.3% | -16.8% | -18.5% | -3.7% | +30.1% | +42.6% | +38.3% | +18.9% | -4.6% | -10.3% | -5.9% | +4.1% |
Range$1.97B – $3.84B
CAGR+6.5%
Avg YoY Growth+5.4%
Median YoY Growth+0.2%
Accrued Manufacturing Costs at Other Companies
Frequently Asked Questions
- What is Pfizer's accrued manufacturing costs?
- Pfizer (PFE) reported accrued manufacturing costs of $2.72B in Q1 2026.
- How has Pfizer's accrued manufacturing costs changed year-over-year?
- Pfizer's accrued manufacturing costs increased by 4.1% year-over-year, from $2.61B to $2.72B.
- What is the long-term trend for Pfizer's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Pfizer's accrued manufacturing costs has grown at a 3.4% compound annual growth rate (CAGR), from $3.05B to $3.61B.